LAUSR

Abstract Introduction Corticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality. Source of data Pubmed, EMBASE, Scopus and Google Scholar databases. Areas of agreement Prolonged glucocorticoids administration leads to secondary osteoporosis. Areas of controversy The optimal management for CIO is controversial. Growing points The present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO. Areas timely for developing research For selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study. Level of evidence I, Bayesian network meta-analysis of randomized clinical trials.